Oral mifepristone for chronic central serous chorioretinopathy

Retina

Volumn 31, Issue 9, 2011, Pages 1928-1936

  Nielsen, Jared S ^a,b   Jampol, Lee M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Wolfe Eye Clinic   (United States)

Author keywords

antiglucocorticoid therapy; central serous chorioretinopathy; central serous retinopathy; glucocorticoid receptor antagonism; mifepristone; optical coherence tomography; RU 486

Indexed keywords

BEVACIZUMAB; MIFEPRISTONE; PLACEBO;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CENTRAL SEROUS RETINOPATHY; CHRONIC CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LIVER FUNCTION; LOW LEVEL LASER THERAPY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA ANGIOGRAPHY; RETINA DETACHMENT; RETINA MACULA EDEMA; SIDE EFFECT; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HORMONE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MIFEPRISTONE; RECEPTORS, GLUCOCORTICOID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 80053363586     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821c3ef6     Document Type: Article

References (13)

1. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984;91:1554-1572.
2. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;8:1057-1062.
3. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;10:1469-1473.
4. Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: A rationale for new treatment strategies. Ophthalmology 2002;109:1765-1766.
5. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina 2007;1:119-122.
6. Carvalho-Recchia CA, Yannuzzi LA, Negrño S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002;10:1834-1837.
7. Clark RD. Glucocorticoid receptor antagonists. Curr Top Med Chem 2008;9:813-838.
8. Cadepond F, Ulmann A, Baulieu EE. RU 486 (mifepristone): Mechanisms of action and clinical uses. Annu Rev Med 1997; 48:129-156.
9. Shin JY,Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011;1:119-126.
10. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina 2008;1:85-93.
11. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003;4:698-703.
12. Meyerle CB, Freund KB, Bhatnagar P, et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007;7:943-946.
13. Golshahi A, Klingmü ller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: A pilot study. Acta Ophthalmol 2010;5:576-581.